The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

Titusville: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved CAPLYTA ...

The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

A new medication for treatment-resistant depression may help a subset of people who carry a specific genetic marker.

The FDA has approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for treating major depressive ...

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Among inpatients at an academic center, serial adjunctive ketamine infusions were no more effective at treating major depression than midazolam, according to a randomized clinical trial published in ...

Researchers from Trinity College, St Patrick’s Mental Health Services, Queen’s University Belfast, Ireland, investigate use of twice-weekly ketamine infusions as an add-on treatment for inpatients wit ...

A 2022 study showed that 28.3% of patients receiving ketamine had a billing diagnosis of depression. McLoughlin's group pointed to evidence that suggested ketamine is more effective than esketamine ...

At lecture, Helen Mayberg presented findings showing electrical impulses in the brain can induce long-term benefits in patients.